Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 3/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.60 |
| ▸ | HTT | P42858 | 4/20 | 0.60 |
| ▸ | STAT3 | P40763 | 3/20 | 0.60 |
| ▸ | MAPT | P10636 | 5/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | HPGD | P15428 | 3/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | NQO2 | P16083 | 3/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.52 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9590284 | 0.82 | TLR8 (0.67) | TLR8SMN1; SMN2MAPTKDM4EALDH1A1 | |
| SCHEMBL180365 | 0.80 | TLR8 (0.65) | TLR8SMN1; SMN2MAPTKDM4EALDH1A1 | |
| SCHEMBL18023079 | 0.79 | HTT (0.69) | TLR8SMN1; SMN2HTTSTAT3MAPT | |
| SCHEMBL29207072 | 0.79 | HTT (0.59) | TLR8SMN1; SMN2HTTSTAT3MAPT | |
| SCHEMBL12969936 | 0.78 | TLR8 (0.62) | TLR8SMN1; SMN2HTTMAPTKDM4E | |
| SCHEMBL28284738 | 0.78 | TLR8 (0.62) | TLR8SMN1; SMN2HTTSTAT3MAPT | |
| SCHEMBL7045347 | 0.78 | TLR8 (1.00) | TLR8SMN1; SMN2KDM4EALDH1A1HPGD | |
| SCHEMBL9589202 | 0.78 | TLR8 (0.62) | TLR8SMN1; SMN2MAPTKDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL27511729 | 0.78 | TLR8 (0.62) | TLR8SMN1; SMN2MAPTKDM4EALDH1A1 | |
| SCHEMBL18023055 | 0.78 | TLR8 (0.62) | TLR8SMN1; SMN2HTTSTAT3MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240398776-A1 | INHIBITORS OF TGF-BETA R1 (ALK5) USEFUL TO TREAT CELL PROLIFERATION DISORDERS | NEXYS THERAPEUTICS, INC. (US) | 2024-12-05 | — | — | US | disclosed |
| US-12102626-B2 | (Pyridin-2-yl)amine derivatives as TGF-BETA R1 (ALK5) inhibitors for the treatment of cancer | NEXYS THERAPEUTICS, INC. (US) | 2024-10-01 | — | — | US | disclosed |
| EP-3902796-B1 | (PYRIDIN-2-YL)AMINE DERIVATIVES AS TGF-BETA R1 (ALK5) INHIBITORS FOR THE TREATMENT OF CANCER | NEXYS THERAPEUTICS INC (US) | 2024-02-07 | — | — | EP | disclosed |
| CN-114507180-B | Methyl-substituted azaheterocyclic compound C (sp 3 ) Method for self dehydroalkenylation of H bonds | 常州大学 | 2023-08-22 | — | — | CN | disclosed |
| US-20220054465-A1 | (PYRIDIN-2-YL)AMINE DERIVATIVES AS TGF-BETA R1 (ALK5) INHIBITORS FOR THE TREATMENT OF CANCER | NEXYS THERAPEUTICS, INC. (US) | 2022-02-24 | — | — | US | disclosed |
| US-20220054465-A1 | (PYRIDIN-2-YL)AMINE DERIVATIVES AS TGF-BETA R1 (ALK5) INHIBITORS FOR THE TREATMENT OF CANCER | NEXYS THERAPEUTICS, INC. (US) | 2022-02-24 | — | — | US | disclosed |
| EP-3902796-A1 | (PYRIDIN-2-YL)AMINE DERIVATIVES AS TGF-BETA R1 (ALK5) INHIBITORS FOR THE TREATMENT OF CANCER | Nexys Therapeutics, Inc. (US) | 2021-11-03 | — | — | EP | disclosed |
| CN-113348167-A | (pyridin-2-yl) amine derivatives as TGF-beta R1(ALK5) inhibitors for the treatment of cancer | 奈可萨斯医药有限公司 | 2021-09-03 | — | — | CN | disclosed |
| WO-2020139636-A1 | (PYRIDIN-2-YL)AMINE DERIVATIVES AS TGF-BETA R1 (ALK5) INHIBITORS FOR THE TREATMENT OF CANCER | NEXYS THERAPEUTICS, INC. (US) | 2020-07-02 | — | — | WO | disclosed |
| WO-2020139636-A1 | (PYRIDIN-2-YL)AMINE DERIVATIVES AS TGF-BETA R1 (ALK5) INHIBITORS FOR THE TREATMENT OF CANCER | NEXYS THERAPEUTICS, INC. (US) | 2020-07-02 | — | — | WO | disclosed |
| EP-1400519-B1 | Respiratory syncytial virus replication inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2007-03-07 | — | — | EP | disclosed |
| US-7071192-B1 | Respiratory syncytial virus replication inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-07-04 | — | — | US | disclosed |
| US-20060058309-A1 | Respiratory syncytial virus replication inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-03-16 | — | — | US | disclosed |
| EP-1400519-A1 | Respiratory syncytial virus replication inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-03-24 | — | — | EP | disclosed |
| EP-1196410-B1 | RESPIRATORY SYNCYTIAL VIRUS REPLICATION INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2004-02-18 | — | — | EP | disclosed |
| CN-1358182-A | Respiratory syncytial virus replication inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2002-07-10 | — | — | CN | disclosed |
| EP-1196410-A1 | RESPIRATORY SYNCYTIAL VIRUS REPLICATION INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2002-04-17 | — | — | EP | disclosed |
| WO-2001000615-A1 | RESPIRATORY SYNCYTIAL VIRUS REPLICATION INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2001-01-04 | — | — | WO | disclosed |
| US-4166862-A | WEIGHT-GAIN PROMOTERS | CHINOIN GYOGYSZER ES VEGYESZETI TERMEKEK GYARA RT. (HU) | 1979-09-04 | — | — | US | disclosed |
| US-4163746-A | ANABOLIC, 5-METHYL-7-ALKOXYISOFLAVONES | CHINOIN GYOGYSZER ES VEGYESZETI TERMEKEK GYARA RT. (HU) | 1979-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12102626-B2 | (Pyridin-2-yl)amine derivatives as TGF-BETA R1 (ALK5) inhibitors for the treatment of cancer | TGFBR1, TGFBR2, ACVR1 | TLR8 1795/4885SMN1; SMN2 3144/4885HTT 4845/4885 |
| US-20060058309-A1 | Respiratory syncytial virus replication inhibitors | NR4A1, NR4A3, NR4A2 | TLR8 1192/4885SMN1; SMN2 1398/4885HTT 4194/4885 |
| US-20240398776-A1 | INHIBITORS OF TGF-BETA R1 (ALK5) USEFUL TO TREAT CELL PROLIFERATION DISORDERS | ACVR1, TGFBR1, ACVRL1 | TLR8 2446/4885SMN1; SMN2 2960/4885HTT 4668/4885 |
| US-20220054465-A1 | (PYRIDIN-2-YL)AMINE DERIVATIVES AS TGF-BETA R1 (ALK5) INHIBITORS FOR THE TREATMENT OF CANCER | TGFBR1, TGFBR2, ACVR1 | TLR8 1795/4885SMN1; SMN2 3144/4885HTT 4845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.